Dean K. Naritoku, M.D.
Department of Neurology
1974 - 1977 Northwestern University, Evanston, Illinois. B.A.;
Biochemistry and Molecular Biology
1981 - 1982 Internship in Internal Medicine, University of
Illinois, Chicago, Illinois
1985 - 1987 Research Instructor in Neurology, Washington University School of Medicine, St. Louis, Missouri
1987 - 1993 Assistant Professor in Neurology, Southern Illinois University School of Medicine, Springfield, Illinois
1988 - 1993 Assistant Professor in Pharmacology,Southern Illinois University School of Medicine, Springfield, Illinois
1988 - present Director of Intensive Neuromonitoring Unit, Memorial Medical Center, Springfield, Illinois
1992 - present Director of EEG laboratory, Memorial Medical Center, Springfield, Illinois
1993 - present Associate Professor in Neurology, Southern Illinois University School of Medicine, Springfield, Illinois1993 - present Associate Professor in Pharmacology, Southern Illinois University School of Medicine, Springfield, Illinois
1993 - present Graduate Faculty, Southern Illinois University Graduate School, Carbondale, Illinois
1994 - present Fellowship Director, Clinical Neurophysiology/Epilepsy, Southern Illinois University School of Medicine, Springfield, Illinois
1995 - present Associate Chair, Department of Neurology, Southern Illinois University School of Medicine
1996 - present Visiting Adjunct Associate Professor of Clinical Pharmacology, University of IL College of Medicine, Peoria, IL
1997 - present Director, Office of Therapeutics Research, Southern Illinois University School of Medicine, Springfield, Illinois
1987 Neurology, American Board of Psychiatry and Neurology
1994-2004 Added Qualifications in Clinical Physiology, American Board of Psychiatry and Neurology
1996 Clinical Pharmacology, American Board of Clinical Pharmacology
1982 - present American Academy of Neurology
1985 - present American Epilepsy Society
1987 - present American Academy for the Advancement of Science
1987 - present American Medical Association
1987 - present Illinois State Medical Society
1987 - 1992 Epilepsy Association of Lincoln Land; Executive Board, 1987 - 1990; Chairman, Professional Advisory Board, 1987 - 1992
1987 - present Society for Neuroscience
1987 - present Sangamon Chapter, Society for Neuroscience; Program director, 1989-1990; President, 1990-1991
1995 - present American Society for Clinical Pharmacology and Therapeutics; Constitution and Bylaws Committee -Vice chair/chair elect 1999-2002; Education Committee-Vice-chair/chair elect 2000-2003
1998 - present American Society for Clinical Neurophysiology
1991 Status Epilepticus Education Project, Epilepsy Foundation of America1991 - present Executive Board, St. John's Hospital School of EEG Technology
1992 Epilepsy Advisory Board, Abbott Laboratories
1993 - 1995 Information Systems Physician Advisory Group (ISPAG), Memorial Medical Center
1996 - present Faculty and Advisory Board Member, J. Kiffin Penry Epilepsy MiniFellowship, Bowman-Gray School of Medicine, Winston-Salem, NC.
1996- 1999 Continuing Education Committee, American Epilepsy Society
1997 - present Ad hoc committee on Clinical Research, American Association of Medical Colleges
1997 Ad hoc committee on Committee Structure and Process, American Society of Clinical Pharmacology and Therapeutics
1998- present Constitution and Bylaws Committee, Vice-chair/chair designate (1999-2001), American Society for Clinical Pharmacology and Therapeutics
1999 - present Education Committee, Vice-chair /chair designate (2000-2003), American Society for Clinical Pharmacology and Therapeutics
2000 - present Scientific Advisory Board, Citizens United for Research in Epilepsy (CURE)
1975 Phi Eta Sigma Honor Society
1985-1986 USPHS Postdoctoral Fellow (5-T-32-NS07205-04)
1986-1987 Seay Neuropharmacology Fellowship
1989 American Epilepsy Society, Young Investigator Travel Award
1989 Moderator, Experimental Seizure Scientific Session, American Epilepsy Society; Boston MA.
1991 Special Recognition Award, Epilepsy Assn. of Lincoln Land
2001 Kingston's Who's Who - Life member #186671
1986 - 1987 Attending in Movement Disorders and Epilepsy Clinic,
Department of Neurology
St. Louis, Missouri
Washington University School of Medicine
St. Louis, Missouri
Sophomore Medical Student Pharmacology lecture series and
Graduate School Neuropharmacology course,
Southern Illinois University School of Medicine
Clinical Neurophysiology/EEG Course
and EEG clinical rotations
Southern Illinois University School of Medicine
Training Program (1991, 1992, 1994) (Peter Pacha, Heidi
Angeles, Danette Gillespie)
Directions for Research and Therapy. Satellite Symposium,
American Epilepsy Society Annual Meeting, 1993.
Jennifer Hott -1995
Carrie Ricketts - 1996
Lacie McDaniel - 1996
Epilepsy and Neurotherapeutics. Springfield, IL
Clinical Aspects. Satellite Symposium at the 21st International
Epilepsy Congress, Sydney, Australia.
Roundtable, American Epilepsy Society Annual Meeting,
San Francisco, CA
Southern IL University
student curriculum in clinical pharmacology)
Southern IL University, Springfield, IL
University of IL at Springfield
University of Ghent, Ghent Belgium
1997- present SIU Department of Neurology
SIU Center for Epilepsy
1998- present J. Kiffin Penry MiniFellowship Programs
1999- present Citizens United for Research in Epilepsy (CURE)
1999 - present Clinical decision making in the management of epilepsy. (CME journal sponsored by the American Epilepsy Society)
Laboratory Research Funding - Principal Investigator
SIU-CRC (23-89): Functional Anatomy of Progressive Seizure Severity and Electroencephalographic Spike-Wave Activity Following Repeated Audiogenic Seizures in the Genetically Epilepsy Prone Rat (GEPR). $4898; 7/1/88-6/30/89.
SIU-CRC (7-90): Functional Anatomy of Progressive Seizure Severity and Electroencephalographic Spike-Wave Activity Following Repeated Audiogenic Seizures in the Genetically Epilepsy Prone Rat (GEPR). $5000; 7/1/89-6/30/90.
Epilepsy Foundation of America: Studies on GABA in Progressive Seizure Severity and Cortical Epileptiform Activity in the Genetically Epilepsy-Prone Rat; $24,829; 4/1/90 - 3/31/91.
SIU-CRC (26-91): Studies on Glycine in Audiogenic Seizures in the Genetically Epilepsy-Prone Rat (GEPR-9). $2500; 7/1/90-6/30/91
SIU-CRC (17-92): Studies on Glycine in Audiogenic Seizures in the Genetically Epilepsy-Prone Rat (GEPR-9). $3400; 7/1/91-6/30/92
SIU-CRC (23-93): Studies on c-fos Expression in the Forebrain During Audiogenic Seizure Repetition. $4325; 7/1/92-6/30/93.
SIU Program Project: Mechanisms of Seizure Susceptibility - Reductions in GABA Efficacy in the Genetically Epilepsy-Prone Rat. $42,768; 12/1/92-11/30/94.
Cyberonics, Inc: Functional Anatomy of Vagus Nerve Stimulation. $25,000. 7/1/93 - 6/30/94.
SIU Program Project: "Studies on GABAA receptor function during aging," $37,509; 3/94-2/96.
NIH/NINDS (R15 NS34142): Antiepileptic Mechanisms of Vagus Nerve Stimulation. $104,077; 6/1/95-5/31/98.
Cyberonics, Inc: "Studies on the role of brain monoamines in the anticonvulsant effect of vagus nerve stimulation (VNS)." (co-principle investigator with R. Browning) $9094; 7/1/95-6/30/97.
SIU Central Research Committee: "Effects of alternative stimulation parameters in experimentally induced seizures. Award amount: $9,800. Project period 7/1/98 - 6/30/99.
Cyberonics, Inc. "An investigation of the capacity of vagus nerve stimulation to alter the course of recovery of function from brain damage in laboratory rats." (Douglas Smith and Robert A. Jenson, co-principal investigators) $40,000. 7/14/98-7/13/00.
SIU Central Research Committee : "Characterization of seizure-evoked arrhythmia." $9,992. 7/1/01-6/30/02.
Clinical Research Funding - Principal Investigator
McNeil Pharmaceutical: Double-Blind Parallel Comparison of Three Doses of Topiramate (Low to Mid Range) and Placebo in Refractory Partial Epilepsy (YD). $129,108; 1988-1990.
McNeil Pharmaceutical : Long Term Effectiveness of Topiramate on Refractory Partial Seizures Topiramate (YK-P and YKP). $113,722; 4/89 - 1995.
McNeil Pharmaceutical: A Double-blind, Placebo-Controlled, Parallel, Efficacy and Safety Study of Topiramate in Patients with Partial Epilepsy followed by Topiramate Single Therapy as Accomplished by the Reduction of concomitant Tegretol (or Dilantin) (YF and YG). $145,363; 4/89 - 1992.
Parke-Davis Pharmaceutical: Gabapentin: An Open-Label Multicenter Study of the Safety and Efficacy of Gabapentin as Monotherapy or Add-on Therapy in the Long-term Treatment of Epileptic Seizures. $47,739; 5/89 - 1993.
Cyberonics, Inc: Vagus Nerve Stimulation for Intractable Partial Epilepsy. $84,586; 11/90-1992.
Abbott Laboratories: Safety of Intravenous Valproate. $6,951; 1992.
Abbott Laboratories: Safety and Efficacy of B.I.D. and Q.I.D. Dosing with Tiagabine HCl Versus Placebo as Adjunctive treatment for Partial Seizures. $ 148,850; 7/1/92-1995.
Parke-Davis Pharmaceutical: Conversion from Marketed Antiepileptic Drug Therapy to Gabapentin (CI-945) Monotherapy in Patients with Complex Partial or Secondarily Generalized Seizures: A Double-Blind, Dose-Controlled , Multicenter Study. (945-082) $78,000; 5/93 - 1995.
Dainippon Pharmaceuticals: Baseline Controlled Safety and Efficacy of Zonisamide in the Treatment of Seizures in Medically Refractory Patients (810-920). $76,750; 8/93 - 1994.
Dainippon Pharmaceuticals: Long-term Safety and Efficacy Evaluation of Zonisamide in the Treatment of Seizures in Medically Refractory Patients and Efficacy Evaluation of Zonisamide Monotherapy (810-921). $153,800; 8/93 - 1999.
Schwabe Pharmaceuticals: Losigamone study. $77,925; 8/94-7/96.
Cyberonics, Inc.: E05: Assessment of vagus nerve stimulation (VNS) for adjunctive treatment of epilepsy patients who have refractory partial onset seizures with alteration of consciousness. $189,875; 4/95-3/97.
Cyberonics, Inc.: XE5: Open-Label Treatment of Refractory Partial Onset Seizures Using Vagus Nerve Stimulation. Principal Investigator - Dean K. Naritoku, M.D. ; $30,000 11/95 - 8/97
Glaxo Wellcome Inc.: Protocol SCAA4001: A Double-Blind, Double-Dummy, Parallel-Group Comparison of Lamotrigine and Divalproex Sodium Monotherapy in Patients with Generalized Seizures. Principal Investigator - Dean K. Naritoku, MD; $52,416; 10/96 - 1999
Ortho-McNeil Pharmaceutical: Protocol CAPSS-027: A Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy of Topamax(r)(Topiramate) Compared to Valproate as Add-on Therapy to Carbamazepine with Special Emphasis on Cognitive Function in Subjects with Partial-Onset Seizures. Principal Investigator - Dean K. Naritoku, MD.; $49,600; 3/97- 1999
Warner-Lambert/Parke-Davis: "Study in patients with partial seizures" (pregabalin). Project period: 4/9/98-4/8/99; award amount: $62,487. This is a randomized, double-blind placebo controlled phase III trial that assesses the efficacy of pregabalin as an add-on therapy.
Warner-Lambert/Parke-Davis: "Study to determine the efficacy in patients with partial seizures": Project period: 4/9/98-4/8/99; award amount $57,050. This is an open-label extension study for patients exiting the blinded phase of the above pregabalin study.
Abbott Laboratories: The Safety and Tolerance of Intravenous Depacon at an
Infusion Rate up to 3.0 mg/kg/min in Subjects with Epilepsy. Award amount: $72,609.
Abbott Laboratories: Comparison of the bioavailability of a depakote extended-release formulation relative to the depakote delayed-release tablet formulation in adult patients with epilepsy on the depakote delayed-release tablet formulation and an enzyme-inducing antiepileptic drug. Award amount: $117,900 (9/1/01-8/30/02)
Elan Pharmaceuticals: A double-blind, randomized, multicenter,
parallel group study to establish dose-response, safety, and efficacy of Zonegran
(zonisamide) as monotherapy in patients with newly diagnosed epilepsy. $60,034
NIH (R01 NS 21281): Neurotransmitter Seizure Mechanisms; Principal Investigator: Carl L. Faingold; $211,851; 9/1/88-8/31/91
Wallace Laboratories: Monotherapy Comparison of Felbamate and Valproate in Partial Seizures. Principal Investigator - M. Steven Evans; $ 84,586.80; 12/89 - 1990.
Wallace Laboratories: A Multicenter, Open-Label, Long-Term Evaluation of the Safety of Felbamate in Subjects with Epilepsy. Principal Investigator - M. Steven Evans; $ 9733; 12/89 - 1993.
Wallace Laboratories: Open-Label, Follow-On, Long-Term Felbamate Therapy in Adult Subjects. Principal Investigator - M. Steve Evans; $36,113; 12/89 - 1993.
NIAAA (AA08591): Neuronal and Neurotransmitter Actions of Ethanol; Principal Investigator Carl L. Faingold; $260,329; 2/1/92- 1/31/95.
NIH (R01 NS 21281): Neurotransmitter Seizure Mechanisms; Principal Investigator: Carl L. Faingold; $311,040; 4/1/92-3/31/95.
Cyberonics: "Studies on the enhancement of memory storage processed by vagus nerve stimulation (VNS)." Principle investigators: R. Jensen; $16,659; 7/1/95-6/30/95.
Naritoku DK, Jensen RA, Browning RA, Clark KA, Smith D and Terry RS, Jr. Methods of treating traumatic brain injury by vagus nerve stimulation. U.S. Patent #6,104,956
1. Naritoku DK, Levine JA, Covey D and Ferrendelli JA. Effects of anticonvulsant gamma-butyrolactones and thiobutyrolactones on GABA-dependent chloride uptake, Biochem. Pharmacol., 1987; 36:797-800.
2. Holland KD, Naritoku DK, McKeon AC, Ferrendelli JA and Covey DF: Convulsant and anticonvulsant cyclopentanones and cyclohexanones. Mol. Pharmacol. 1990; 37:98-103.
3. Naritoku DK, Mecozzi LB, Stryker MT, and Faingold CL. Repetition of audiogenic seizures in genetically epilepsy-prone rats induces cortical epileptiform activity and additional seizure behaviors. Exp. Neurol. 1992;115:317-324.
4. Naritoku DK, Morales A, Pencek TL and Winkler D. Chronic Vagus Nerve Stimulation Increases the Latency of the Thalamocortical Somatosensory Evoked Potential. Pacing and Clin. Elecrophysiol. 1992; 15 (II): 1572-1578.
5. Faingold CL, Naritoku DK, Copley CA, Randall MR, Riaz A, Boersma-Anderson CA, and Arneric SP. Glutamate in the Inferior Colliculus Plays a Critical Role in Audiogenic Seizure Initiation. Epilepsy Res. 1992; 13:95-105.
6. Matsuoka Y, Rakonczay A, Giacobini E, Naritoku D. L-Beta-methylamino-alanine-induced behavioral changes in rat. Pharmacol. Biochem. Behav., 1993; 44:727-734.
7. Faingold CL, Randall ME, Naritoku DK and Boersma-Anderson, CA. Non-Competitive and Competitive NMDA Antagonists Exert Anticonvulsant Effects by Actions on Different Sites Within the Neuronal Network for Audiogenic Seizures Exp. Neurol., 1993, 119:198-204.
8. Summers, K.L., Cuadra, G., Naritoku, D. and Giacobini, E. Effects of Nicotine on Levels of Acetylcholine and Biogenic Amines in Rat Cortex. Drug Devel. Res., 1994, 31:108-119.
9. Naritoku DK, Terry WJ, and Helfert, RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res., 1995, 22:53-62.
10. Ramsay R.E., Augustinsson L.E., Naritoku D.K., Willis J.K., Treig T., Wernicke J.F. and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 2. Clinical and Pharmacological Correlates of Efficacy. Epilepsia , 1994, 35:627-636.
11. Patel J and Naritoku, DK. Gabapentin for the treatment of hemifacial spasm. Clin. Neuropharmacol., 1996. 19:185-188.
12. Evans, M.S., Naritoku, D.K., Ghobrial, M., Couch, J.R. Dihydroergotamine (DHE)-induced stroke in a patient with saggital sinus thrombosis. Clin. Neuropharmacol., 1996, 19:177-184.
13. Takaya M, Terry WJ and Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia, 1996, 37:1111-1116.
14. Campbell KCM, Naritoku DK, Evans MS, Hughes LF and Rybak LP. Is valproic acid ototoxic? Am. J. Audiology, 1996, 5:7-10.
15. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL, Salinsky MC, Osorio I, Ristanovic, Labiner DM, Jones JC, Murphy JV, Ney GC and Wheeless JW. Vagus nerve stimulation therapy for partial onset seizures. Neurology, 1998. 51:48-55.
16. Clark KB, Smith DC, Hassert DL, Browning RA, Naritoku DK and Jensen RA. Post-training electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. Neurobiol. Learn. Mem. 1998, 70:364-373.
17. Clark KB, Naritoku DK, Smith DC, Browning RA and Jensen RA. Enhanced recognition memory following vagus nerve stimulation in human subjects. Nature Neurosci., 1999, 2:94-98.
18. Naritoku DK and Mueed S. Intravenous loading of valproate for epilepsy. Clin. Neuropharmacol.,, 1999, 2:102-106.
19. Espinosa J, Aiello MT and Naritoku DK. Revision and removal of stimulation electrodes following long-term therapy with the vagus nerve stimulator. Surgical Neurol. , 1999, 51:659-664.
20. Caspary DM, Holder-Shanklin TH, Millbrandt J, McKernan RM and Naritoku DK. Changes in GABAA receptor composition and function in the rat inferior colliculus as a consequence of aging. Neurosci., 1999, 93: 307-302.
21. Sirven JI, Sperling M, Naritoku D, Schachter S, Labar D, Holmes M, Wilensky A, Cibula J, Labiner DM, Bergen D, Nadkarni M, Harvey J, Dasheiff R, Morris GL, Ristanovic R, Richards B, Sanchez J. Efficacy and tolerability of vagus nerve stimulation therapy for epilepsy in older adults. Neurology, 2000, 54:1179-82.
22. Naritoku DK and Sinha S. Prolongation of midazolam half-life following sustained infusion for status epilepticus. Neurology, 2000, 54:1366-8.
23. Sinha S, and Naritoku DK. Intravenous valproate is well tolerated in hemodynamically unstable patients with status epilepticus. Neurology, 2000, 55:722-4.
24. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, Reed R, Collins S, Tecoma E, Morris GL, Vaughn B, Naritoku DK, Henry T, Labar D, Gilmartin R, Labiner D, Osorio I, Ristanovic R, Jones J, Murphy J, Ney G, Wheless J, Lewis P, Heck C. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia, 2000, 41:1195-1200.
25. DeGiorgio CM, Thompson J, LewisP, Arrambide S, Naritoku D, Handforth A, Labar D, Mullin P, Heck C, and the VNS U.S. Study Group. Vagus nerve stimulation: Analysis of device parameters in 154 patients during the long-term XE5 study. Epilepsia, 2001, 42: 1017-1020.
26. Feng H-J, Naritoku DK, Randall ME, Faingold CL. Modulation of audiogenically kindled seizures by GABA-related mechanisms in the amygdala, Exp. Neurol., 2001 (in press).
1. Kalkanis JG, Krishna MD, Espinosa JA, Naritoku DK. Self-inflicted vocal cord paralysis in two patients with vagus nerve stimulators. Submitted to J. Neurosurg.
2. Ramsay RE, Cantrell D, Collins SD, Walch JK, Naritoku DK, Cloyd JC, Sommerville KW, and the Depacon Rapid Infusion Study Group. Safety and tolerance of rapidly infused Depacon(r): A randomized trial in subjects with epilepsy. Submitted to Neurology.
3. Espinosa JA, Verma-Ahuja S, Naritoku DK, Farris C, Evans MS. Human vagus nerve compound action potentials recorded during implantation of a vagus nerve stimulator. Submitted to J. Clin. Neurophysiol.
1. Dailey JW and Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem. Pharmacol.,1997, 52:1323-1329.
2. Hernandez TD and Naritoku DK. Traumatic brain injury and neurorehabilitation: a re-appraisal. Neurology, 1997, 48:803-806.
1. Faingold CL and Naritoku DK. Genetically epilepsy-prone rat: neuronal networks and amino acid transmitters. In: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders, Faingold CL and Fromm GL (eds). Boca Raton, Florida: CRC Press, 1991, pp. 277-308.
2. Naritoku DK and Hernandez, TD. Posttraumatic Epilepsy and Neurorehabilitation. In: Traumatic Brain Injury Rehabilitation:(Ashley MJ and Krych DK eds). Boca Raton, Florida: CRC Press, 1995.
Publications Resulting From Multicenter Studies
1. Ben-Menachem E, Hufnagel, Wilder, Stefan, Mirza and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 1. Effect on Seizures in a Controlled Study. Epilepsia, 1994, 616-626.
2. George R, Salinsky M, Kuzniecky R, Rosenfeld W, Bergen D, Tarver WB, Wernicke JFand First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. Epilepsia, 1994, 35(3):637-43.
3. Salinski, Manon, Kuzniecki, Rosenfeld and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 4. Long-Term Effects and Quality of Life. Epilepsia, in press.
4. The vagus nerve stimulation study group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurol., 1995, 45:224-230.
5. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM and Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 46(6):1684-90.
6. Devinsky O, Leppik I, Willmore LJ, Pellock JM, Dean C, Gates J, Ramsay RE. Safety of intravenous valproate. Ann Neurol., 1995, 38(4):670-4.
1. Naritoku DK. Acute and chronic side effects of antiepileptic drugs in adults. In: Antiepileptic drugs: Drug interactions and adverse effects, J.M. Pellock (ed), Deerfield IL, Discovery International, 1995, pp. 12-19. (CME publication)
2. Naritoku DK. The use of anticonvulsants for the treatment of epilepsy, migraine and bipolar disorder: Epilepsy. In: Current Pharmacy Topics: A continuing education program for pharmacists. Champaign IL: Grotelueschen Associates, 1995, pp. 4-12. (CME publication)
3. Naritoku DK. Mechanisms of antiepileptic vagus nerve stimulation. In: International Medical Forum 102 (P. Chauvel, ed). Oxford UK: Blackwell Science, 1998
4. Ramsay RE and Naritoku DK. Treatments of choice for tonic-clonic seizures. Rancho Mirage CA, Annenberg Center for Health Sciences, 1998. (CME publication)
5. Naritoku DK. Use of intravenous valproate in a patient experiencing breakthrough seizures. Epilepsy: Case-based self-study for practicing neurologists., Medical College of Virginia, 1998, 1:12-13.
6. Naritoku DK. Intravenous therapies for seizures. Epilepsy MiniFellowship Lecture Series. J. Kiffin Penry MiniFellowship Program, 1998.
7. Naritoku DK and Sinha S. Status epilepticus in a patient with "Do not resuscitate" (DNR) orders. Epilepsy: Case-based self-study for practicing neurologists., Medical College of Virginia, 1999, 2:4-5.
8. French J, Naritoku DK, Ramsay RE and Tatum WO (eds) Best practices in epilepsy - DIalogues in Neurotherapeutics. Health Learning Systems/University of Kentucky Continuing Education Office, 2001.
9. Naritoku DK. Outcome of status epilepticus treated with intravenous valproate. Advanced Studies in Medicine, Johns Hopkins Univerisity, 2001 in press.
10. Naritoku DK (editor), Ramsay RE, Wheless JW. Use of intravenous antiepileptic drugs in emergency situations. Dannemiller Memorial Educational Foundation 2001 in press.
11. Naritoku DK (editor) A better understanding of antiepileptic drugs and how they function. Access Medical Group, in press.
1. Naritoku DK, Levine JA, Covey D and Ferrendelli JA. Comparative Anticonvulsant Effects of Ethosuximide, Valproic Acid, Gamma Butyrolactones and Thiobutyrolactones, Soc. Neurosci. Abstr., 1986.
2. Naritoku DK, McKeon AC, Levine JA, Covey DF and Ferrendelli JA. Structure-Activity Relationships of Alpha-alkyl-submitted Gamma-butyrolactones and Thiobutyrolactones. Epilepsia 1987.
3. Naritoku DK, Mecozzi LB and Faingold CL. Repeated Audiogenic Seizures (AGS) Produce Epileptiform Cortical Activity and Increased Seizure Severity in Genetically Epilepsy-Prone Rats (GEPR-9s). Generalized Epilepsy Symposium Abstr., 1988.
4. Naritoku DK, Stryker MT, Mecozzi LB, Copley CA and Faingold CL. Gabapentin Reduces the Severity of Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rats (GEPR-9), Epilepsia., 1988.
5. Naritoku DK, Mecozzi LB and Faingold CL. Effects of Repeated Audiogenic Seizures (AGS) on Seizure Severity and EEG in Two Substrains of the Genetically Epilepsy-Prone Rat (GEPRs), Soc. Neurosci. Abstr., 1988;14:252.
6. Naritoku DK, Mecozzi LB, Randall ME and Faingold CL. Infusions of GABA Agonists or 2-APH into Amygdala (AMY) or Medical Geniculate (MGB) Reversibly Reduce Seizure Duration and Clonus after Repeated Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rat (GEPR-9). Soc. Neurosci. Abstr. 1989;15:46.
7. Naritoku D.K., Randall M.E., and Faingold C.L. Microinfusions of GABA Agonists and 2-APH into Amygdala Reduce Seizure Duration and Clonus in Repeated Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rat (GEPR-9). Epilepsia, 30:698, 1989.
8. Naritoku DK, Mecozzi LB, Randall ME and Faingold CL. Effects of glycine and milacemide, a glycine prodrug, on audiogenic seizures in the genetically epilepsy-prone rat (GEPR-9). Soc. Neurosci. Abstr. 1990;16:785.
9. Naritoku DK, Matsuoka Y, Rakonczay Z and Giacobini E. Intraventricular infusions on L-ß-Methylamino-alanine (L-BMAA) result in convulsive seizures and cortical epileptiform discharges. Epilepsia 1990;31:608.
10. Naritoku DK, Morales A and Winkler D. Chronic Vagus Nerve Stimulation Prolongs the Latency of the Thalamocortical (N20) Response of Somatosensory Evoked Potentials. Epilepsia., 32(S3):85-86, 1991.
11. Naritoku DK, Campbell C, Evans, MS and Hughes L. Does valproate affect hearing? Epilepsia, 1992
12. Naritoku DK, Willis J, Monon-Espaillat, R, and NCP study group. Patient Activated "Therapeutic Bursts" of Stimulation Delivered Via the Vagus Nerve. Epilepsia, 33 (S3):109, 1992.
13. Ramsay E, Ben-Menachem E, Upton A, Naritoku D, Ristanovic R and NCP Study Group. One year follow-up of 29 patients with refractory epilepsy treated in a controlled study of vagal stimulation. Epilepsia, 33 (S3):102, 1992.
14. Naritoku DK, Campbell K, Evans MS, Hughes L. Does Valproate Administration Alter Auditory Threshold? Epilepsia 1992; 33(S3):109-110.
15. Naritoku D, Willis J, Manon-Espillat R, NCP Study Group. Patient-Activated "Therapeutic Bursts" of Stimulation Delivered via the Vagus Nerve. Epilepsia 1992; 33(S3):102.
16. Campbell KCM, Evans MS, Naritoku DK, Hughes LF. Is valproic acid ototoxic? ARO Abstr 1993; 144.
17. Uthman BM, Ben-Menachem E, Ramsey RE, Naritoku D, Hufnagel A. 18-month follow-up of 32 epilepsy patients receiving vagus nerve stimulation (VNS). Neurology, 1993; 43:A161.
18. Uthman BM, Ramsay E, Naritoku DK, Manon-Espaillat R, Sonnen AEH. One year efficacy results of therapeutic vagus nerve stimulation (VNS) in 61 epilepsy patients. Epilepsia, 34(S2): 192-193. 1993.
19. Naritoku DK, Beckman SL, Evans MS. GABAA receptor efficacy is reduced in the cerebral cortex of the genetically epilepsy-prone rat (GEPR-9). Soc. Neurosci Abstr, 1993.
20. Naritoku DK, Terry WJ, Faingold CL, Helfert RH. Forebrain fos expression during audiogenic seizure repetition in the genetically epilepsy-prone rat (GEPR-9). Epilepsia 1993, 34(S6):22.
21. Chakravarty DN, Faingold CL, Terry WJ, and Naritoku DK. Audiogenic seizures in the genetically epilepsy-prone rat induce c-fos proto-oncogene expression in the inferior colliculus and periaqueductal gray. Soc. Neurosci Abstr, 1993.
22. Naritoku DK and Beckman SL. Reduction of GABAA receptor efficacy in the genetically epilepsy-prone rat: differential response to modulation by a cyclic AMP analog. Epilepsia, 34(S6):76.
23. Terry WJ and Naritoku DK. Patterns of fos production in the forebrain following intermittent vagus nerve stimulation. Epilepsia, 34(S6):8-9, 1993.
24. Uthman, B., Wilder, B.J., Ramsay, E., Naritoku, D. Follow-up of 53 refractory epilepsy patients receiving vagus nerve stimulation for 18 months. Epilepsia, 34(S6):29.
25. Uthman BM, Wilder BJ, Ramsay E, Ben-Menachem E, Naritoku D. Long term follow-up of 70 refractory partial epilepsy patients receiving vagus nerve stimulation. Neurology, 43:A161.
26. Naritoku DK, Terry WJ and Takaya M. Intermittent vagus nerve stimulation activates brainstem noradrenergic nuclei. Epilepsia, 1994.
27. Naritoku, D.K., and the Vagus Nerve Stimulation Study Group. Vagus nerve stimulation: continuation rates as a measure of therapeutic outcome - results from four studies. Epilepsia, 1996
28. Clark, K.B., Smith, D.C., Hassert, D.L., Browning, R.B., Naritoku, D.K., and Jensen, R.A. Posttraining electrical stimulation of vagal afferents with concomitant efferent inactivation enhances retention performance in the rat. Soc. Neurosci. Abstr, 1996.
29. Naritoku DK, Mikels JA. Vagus nerve stimulation (VNS) attenuates electrically kindled seizures. Epilepsia 1996; 37(S5):75.
30. Rodgers-Neame NT, Aiello MT, Naritoku DK. Smoking is related to unpleasant laryngeal symptoms in persons receiving vagus nerve stimulation for seizure control. Epilepsia 1996; 37(S5):S176.
31. Terry WJ, Takaya M, Naritoku DK. Regional changes in brain glucose metabolism in rats following anticonvulsant stimulation of the vagus nerve. Epilepsia 1996; 37(S5):117.
32. Naritoku DK and Mikels JA. Vagus nerve stimulation (VNS) is antiepileptogenic in the electrical kindling model. Epilepsia 1997; 38 (S3):3.
33. Sirven JI, Bergen DC, Cibula JE, Dahieff RM, Harvey JH, Holmes MD, Labar DR, Labiner DM, Morris GL, Nadkarni MA, Naritoku DK, O'Donovan C, Ojemann LM, Richards BA, Ristanovic RK, Sanchez JD, Scales DF, Schachter SC, Wilensky AJ and Sperling MR. Vagus nerve stimulation of epilepsy in adults 50 years and older: a multicenter study. Neurology 1999; 6(S2):A108-109.
34. Faingold CL, Naritoku DK, Randall ME. The role of inhibitory and excitatory glycine receptors in modulation of audiogenic seizures in the inferior colliculus (IC). Epilepsia 1999: 40(S7): 39.
35. Naritoku DK, Smith MC, Penry MD. Intensive training of primary care physicians in epilepsy: Result study. Epilepsia 1999: 40(S7): 232.
36. Sinha S, Naritoku DK. Prolongation of midazolam half-life following sustained infusion for status epilepticus. Neurology 2000, 54(S3): A307.
37. Raisinghani M, D. Casebeer D, Naritoku D, Faingold C. Modulation of postictal depression: role of opioid receptor subtypes. Soc. Neurosci. Abstr 2000.
38. Cantrell DT, Ramsay ER, Collins SD, Walch JK, Gu Y, Deaton R, Naritoku DK, Gates JR, Kuzniecky RI, Morris GL, Cloyd JC, Raroque H. Rapid infusions of Depacon are safe and well tolerated. Epilepsia 2000; 41(S7): 253.
39. Naritoku DK, Sinha S. Outcome of staus epilepticus treated with intravenous valproate. Neurology 2001 (S3): A235-236.
40. Darbin OE, Casebeer DJ, Naritoku DK. Cardiac arrhythmia occurs during the immediate postictal state following n=maximal electroshock (MES) in freely moving rats. Soc. Neurosci. Abstr. 2001 in press.
41. Darbin OE, Casebeer DJ, Naritoku DK. Cardiac arrhythmia associated with maximal electroshock (MES)-induced seiuzres are most influenced by parasympathetic activity. Epilepsia 2001 in press.
42. Brozman B, Tatum WO, Ferreira JA, Slater JD, Naritoku DK, Gallo BV, McJilton JS, Ramsay RE. Vagal nerve stimulation: efficacy of standard versus rapid cycling. Epilepsia 2001 in press.
43. Dedeurwaerdere S, Vonck K, D'have M, Naritoku D, Grisar T, Marescaux C. Vagus nerve stimulation in GAERS: results of a pilot study. Epilepsia 2001 in press.
44. Naritoku DK, Hulihan J, Kamin M, Karim R, Olsen W. Reduction of AED co-therapy improves tolerability of add-on therapy with topiramate: a novel randomized study. Epilepsia 2001 in press.
| Supported By:
||FAQs | Supported By | Epilepsy Links | Contact Us|